دورية أكاديمية
Chloroquine has shown high therapeutic efficacy against uncomplicated Plasmodium vivax malaria in southern Ethiopia: seven decades after its introduction
| العنوان: | Chloroquine has shown high therapeutic efficacy against uncomplicated Plasmodium vivax malaria in southern Ethiopia: seven decades after its introduction |
|---|---|
| المؤلفون: | Anteneh Kassahun Mare, Hussein Mohammed, Heven Sime, Henok Hailgiorgis, Kale Gubae, Bekuretsion Gidey, Mebrahtom Haile, Gudissa Assefa, Worku Bekele, Sarah Auburn, Rick Price, Jonathan B. Parr, Jonathan J. Juliano, Geremew Tasew, Solomon Mequanente Abay, Ashenafi Assefa |
| المصدر: | Malaria Journal, Vol 23, Iss 1, Pp 1-11 (2024) |
| بيانات النشر: | BMC, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Arctic medicine. Tropical medicine LCC:Infectious and parasitic diseases |
| مصطلحات موضوعية: | Plasmodium vivax, Chloroquine, Therapeutic efficacy, Arba Minch, Ethiopia, Arctic medicine. Tropical medicine, RC955-962, Infectious and parasitic diseases, RC109-216 |
| الوصف: | Abstract Background Plasmodium vivax malaria is a leading cause of morbidity in Ethiopia. The first-line treatment for P. vivax is chloroquine (CQ) and primaquine (PQ), but there have been local reports of CQ resistance. A clinical study was conducted to determine the efficacy of CQ for the treatment of P. vivax malaria in southern Ethiopia. Methods In 2021, patients with P. vivax mono-infection and uncomplicated malaria were enrolled and treated with 25 mg/kg CQ for 3 consecutive days. Patients were followed for 28 days according to WHO guidelines. The data were analysed using per-protocol (PP) and Kaplan‒Meier (K‒M) analyses to estimate the risk of recurrent P. vivax parasitaemia on day 28. Results A total of 88 patients were enrolled, 78 (88.6%) of whom completed the 28 days of follow-up. Overall, 76 (97.4%) patients had adequate clinical and parasitological responses, and two patients had late parasitological failures. The initial therapeutic response was rapid, with 100% clearance of asexual parasitaemia within 48 h. Conclusion Despite previous reports of declining chloroquine efficacy against P. vivax, CQ retains high therapeutic efficacy in southern Ethiopia, supporting the current national treatment guidelines. Ongoing clinical monitoring of CQ efficacy supported by advanced molecular methods is warranted to inform national surveillance and ensure optimal treatment guidelines. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1475-2875 |
| Relation: | https://doaj.org/toc/1475-2875 |
| DOI: | 10.1186/s12936-024-05009-7 |
| URL الوصول: | https://doaj.org/article/8325b6b3233b49b794a5f82bb12d771a |
| رقم الأكسشن: | edsdoj.8325b6b3233b49b794a5f82bb12d771a |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 14752875 |
|---|---|
| DOI: | 10.1186/s12936-024-05009-7 |